COMING SOON FROM MDOUTLOOK and HRA-HEALTHCARE RESEARCH & ANALYTICS –
Immuno-oncology is poised to become a disruptive force across the cancer care spectrum. With any new treatment innovations, it brings with it uncertainty about the future of care. The targeted patient population and the need to drive return on research and commercialization investments, combined with a developing picture of improved outcomes over current paradigms create challenges for pharmaceutical and biotech manufacturers in bringing these products to market and making them profitable.
MDoutlook’s newest study, Immuno-Oncology: Assessing the Impact and Implications in an Evolving Market is a partnership between MDoutlook and HRA that will dive into and clarify the rapidly developing landscape of immuno-oncology. The research will deliver to biotech and pharmaceutical manufacturers with key perspectives gained from oncologists, payers, and health systems administrators. Readers will walk away with an understanding of how to more successfully shape and target sales, marketing, and educational approaches for maximum commercial efficacy across these stakeholders. Order the report here.
Research Topics include:
- Practitioner perspectives on immuno-oncology including current and pipeline products and market leaders
- Payer perspectives on immuno-oncology including the value of treatments, MCO formulary and clinical pathway access and unmet educational needs
- Key roles beyond the immuno-oncology sales teams including the right mix between reimbursement specialists, nurse educators, MSLs, and account managers
- And more!
Key Applications to include:
- Formulate and execute strategies relative to immuno-oncology products and stakeholders in patient care and reimbursement
- Leverage current and emerging decision-makers for more targeted promotion of products and services
- Differentiate needs based on composition, decision-making paradigms, and other key variables
- Ultimately develop stronger market strategies for immuno-oncology by understanding how to tailor message platforms and educational programs to the appropriate target
MDoutlook delivers targeted disease intelligence. Governed by top thought leaders and in-house MD/PhD medical experts, MDoutlook is powered by accessing a proprietary network of 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, autoimmune diseases. Clients include all of the major pharmaceutical companies, biotech and diagnostic companies as well life science agencies.
About HRA – Healthcare Research & Analytics
HRA – Healthcare Research & Analytics is a consultative healthcare market research practice leveraging a flexible spectrum of solutions to support decision-making and strategy development across healthcare channels with particular expertise in the hospital setting. HRA’s team of highly-experienced market researchers combines deep domain expertise in healthcare, science, business, and statistics with a passion for uncovering insights. HRA’s portfolio of offerings encompasses quantitative and qualitative, custom and syndicated market research services to support the business needs of the pharmaceutical, biotech, and medical device markets. HRA’s people and its products provide the healthcare market with actionable intelligence – facilitating better business decisions.
To discuss how MDoutlook can drive your strategic decision-making through deep insight and ThoughtLeader intelligence, please call 888-3outlook of contact us here.
We are very pleased to announce that the 50th Annual Meeting of ASCO (American Society of Clinical Oncology) has now published two approved abstracts based on research performed by MDoutlook on behalf of Dr. Kenneth Miller, Sinai Hospital in Baltimore, MD. The posters will be presented at the meeting in Chicago on May 30 – June 3.
The abstracts are focused on ill-defined areas in cancer care and can be found here:
- Abstract e20510: Use of the word “death” in cancer care
- Abstract e20600: Do patients need lifelong follow-up? Why?
This research is part of our commitment to advance care and give back to the cancer community. Earlier, MDoutlook research in the area of cutaneous T-cell lymphoma was published at the 2011 ASCO meeting. Our research and insight has been included in many commercial and scientific meetings, presentations and plans.
If you are at ASCO this year, please pay us a visit at booth 6038 to discuss your intelligence and insights needs in oncology. Or contact us here.
We look forward to working with you on your disease intelligence projects.
We are very pleased to announce that the Scientific Program Committee has accepted two abstracts submitted to the 50th Annual Meeting of ASCO (American Society of Clinical Oncology) based on research performed by MDoutlook on behalf of Dr. Kenneth Miller, Sinai Hospital in Baltimore, MD. The posters will be presented at the meeting in Chicago on May 30 – June 3.
The abstracts are currently under embargo by ASCO and will be released on May 14 at 5pm EDT on this website. However, we can share meanwhile time that each study focused on ill-defined areas in cancer care:
- the definition and use of the word ‘Death’ by oncologists in cancer care
- oncologists’ perceptions of their patients’ residual risk of recurrence as well as the duration and reasons for follow-up care
Stay tuned to this site as we will share access to the full abstracts once the embargo has been lifted. Check this link for our abstract on cutaneous T-cell lymphoma accepted for the 2011 ASCO meeting. Our research and insight has been included in many commercial and scientific meetings, presentations and plans.
MDoutlook is an independent, on-going, global clinician information initiative developed in collaboration with leading disease experts. Our mission is to improve understanding of today’s medical practice by bringing together practitioners for information sharing, leading to better patient care. Our work focuses on specialty diseases, including Oncology, Hematology, Immunologic Diseases and many more.
Please contact us here or give us a call at +1.404.496.4136 to discuss how we can help you.
The treatment paradigm in oncology is shifting rapidly. With the advent of targeted therapies, the importance of molecular diagnostics is rapidly growing. The role of the cancer pathologist is changing, and so is the oncologist’s reliance on molecular markers in their clinical decision-making. Shared decision-making is common.
MDoutlook delivers deep insight into the changes in clinical decision-making; by specialist, by tumor-type, by stage of disease, even by molecular sub-type. In the past six months, our clients have commissioned US and EU studies in lung cancer, melanoma, renal cell carcinoma, breast cancer, non-Hodgkin lymphoma, CLL and several other malignancies.
Focal point in all studies has been the role of diagnostics and impact on clinical decision-making; e.g. this recent study in NSCLC:
Interested in similar insight customized to your specific needs? By accessing the largest validated global panel of 75,000+ cancer HCPs (including onco-paths), MDoutlook collects and analyzes ground-level information to answer your business critical questions.
Want to know more about our existing studies to quickly answer a question? Our team of medical analysts can data-mine and meta-analyze our existing research to provide a targeted answer to your questions.
Contact us through this form or give us a call at +1.404.496.4136. And you can also visit us at the upcoming ASCO meeting in booth 6038.